Craft

Ixico

Stock Price

£0.1

2024-10-29

Market Capitalization

£4.6 M

2024-10-29

Revenue

£6.5 M

FY, 2025

Ixico Summary

Company Summary

Overview
Ixico is a neuroimaging provider. It is helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. The company offers trial design and consultation, project and data management, imaging site set-up, analysis, etc.
Type
Public
Status
Active
Founded
2004
HQ
London, GB | view all locations
Website
https://ixico.com/
Cybersecurity rating
Sectors

Key People

  • Charles Spicer

    Charles Spicer, Non-Executive Chairman

  • Mark Warne

    Mark Warne, Non-Executive Director

  • Romina Oxborough

    Romina Oxborough, Senior Vice-President Operations

  • Giulio Cerroni

    Giulio Cerroni, Chief Executive Officer

LocationsView all

2 locations detected

  • London, England HQ

    United Kingdom

    4th floor, Griffin court, 15 Long Ln, Barbican

  • Wilmington, DE

    United States

    251 Little Falls Dr

Ixico Financials

Summary Financials

Revenue (FY, 2025)
£6.5M
Gross profit (FY, 2025)
£3.4M
Net income (FY, 2025)
(£1.7M)
Cash (FY, 2025)
£3.5M
EBIT (FY, 2025)
(£2.5M)
Enterprise value
$1.3M

Footer menu